Guadalupe Manrique Maldonado

Dr. Guadalupe Manrique Maldonado

Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA
orcid

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2011 in European Journal of Pharmacology
Verified
Journal Article
Closed access
Abimael González-HernándezAbimael González-Hernández
Abimael González-Hernández
Guadalupe Manrique MaldonadoGuadalupe Manrique Maldonado
Guadalupe Manrique Maldonado
JLJair Lozano-Cuenca
Jair Lozano-Cuenca
EMEnriqueta Muñoz-Islas
Enriqueta Muñoz-Islas
David CenturiónDavid Centurión
David Centurión
CVCarlos M. Villalón
Carlos M. Villalón

1 December 2013 in European Journal of Pharmacology
Verified
Journal Article
Closed access
BMBruno Antonio Marichal-Cancino
Bruno Antonio Marichal-Cancino
Guadalupe Manrique MaldonadoGuadalupe Manrique Maldonado
Guadalupe Manrique Maldonado
AAAlain H. Altamirano-Espinoza
Alain H. Altamirano-Espinoza
IRInna Ruiz-Salinas
Inna Ruiz-Salinas
Abimael González-HernándezAbimael González-Hernández
Abimael González-Hernández
CVCarlos M. Villalón
Carlos M. Villalón

2 May 2017 in British Journal of Pharmacology
Verified
Journal Article
Closed access
PDF file
VAV H Avilés-Rosas
V H Avilés-Rosas
EREduardo Rivera-Mancilla
Eduardo Rivera-Mancilla
BMBruno Antonio Marichal-Cancino
Bruno Antonio Marichal-Cancino
Guadalupe Manrique MaldonadoGuadalupe Manrique Maldonado
Guadalupe Manrique Maldonado
AAA H Altamirano-Espinoza
A H Altamirano-Espinoza
CVCarlos M. Villalón
Carlos M. Villalón

1 October 2020 in Epilepsy Research
Verified
Journal Article
Closed access
BVBenjamin Villasana-Salazar
Benjamin Villasana-Salazar
RHRebeca Hernández-Soto
Rebeca Hernández-Soto
MGMaría Estefanía Guerrero-Gómez
María Estefanía Guerrero-Gómez
BOBenito Ordaz
Benito Ordaz
Guadalupe Manrique MaldonadoGuadalupe Manrique Maldonado
Guadalupe Manrique Maldonado
FPFernando Peña-Ortega
Fernando Peña-Ortega

30 August 2013 in British Journal of Pharmacology
Verified
Journal Article
Open access
PDF file
AAA H Altamirano‐Espinoza
A H Altamirano‐Espinoza
Abimael González-HernándezAbimael González-Hernández
Abimael González-Hernández
Guadalupe Manrique MaldonadoGuadalupe Manrique Maldonado
Guadalupe Manrique Maldonado
BMBruno Antonio Marichal-Cancino
Bruno Antonio Marichal-Cancino
IRI Ruiz‐Salinas
I Ruiz‐Salinas
CVCarlos M. Villalón
Carlos M. Villalón
Background and Purpose: Quinpirole (a dopamineD2‐like receptor agonist) inhibits the cardioaccelerator sympathetic outflow in pithed rats by sympathoinhibitoryD2‐like receptors. The present study was designed to identify pharmacologically the specificD2‐like receptor subtypes (i.e.D2,D3andD4) involved in this sympathoinhibition by quinpirole.Experimental Approach: One hundred fourteen maleWistar rats were pithed, artificially ventilated with room air and prepared for either preganglionic spinal (C7‐T1) stimulation of the cardioaccelerator sympathetic outflow (n= 102) or i.v. bolus injections of exogenous noradrenaline (n= 12). This approach resulted in frequency‐dependent and dose‐dependent tachycardic responses, respectively, as previously reported by our group.Key Results: I.v. continuous infusions of quinpirole (0.1–10 μg kg−1 min−1), but not of saline (0.02 mL min−1), dose‐dependently inhibited the sympathetically induced tachycardic responses. Moreover, the cardiac sympathoinhibition induced by 3 μg kg−1 min−1quinpirole (which failed to affect the tachycardic responses to i.v. noradrenaline) was: (i) unchanged after i.v. injections of the antagonistsSB‐277011‐A(D3; 100–300 μg kg−1) or L‐745,870 (D4; 30–100 μg kg−1); and (ii) markedly blocked and abolished by, respectively, 100 and 300 μg kg−1of theD2preferring receptor subtype antagonist L‐741,626. These doses of antagonists, which did not affectper sethe sympathetically induced tachycardic responses, were high enough to completely block their respective receptors.Conclusions and Implications: The cardiac sympathoinhibition induced by 3 μg kg−1 min−1quinpirole involves the dopamineD2receptor subtype, with no evidence for the involvement of theD3orD4subtypes. This provides new evidence for understanding the modulation of the cardioaccelerator sympathetic outflow.

27 July 2012 in European Journal of Pharmacology
Verified
Journal Article
Closed access
BMBruno Antonio Marichal-Cancino
Bruno Antonio Marichal-Cancino
Abimael González-HernándezAbimael González-Hernández
Abimael González-Hernández
Guadalupe Manrique MaldonadoGuadalupe Manrique Maldonado
Guadalupe Manrique Maldonado
IRInna I. Ruiz-Salinas
Inna I. Ruiz-Salinas
AAAlain H. Altamirano-Espinoza
Alain H. Altamirano-Espinoza
CVCarlos M. Villalón
Carlos M. Villalón